What is Maxim Group’s Estimate for KindlyMD Q2 Earnings?

KindlyMD, Inc. (NASDAQ:NAKA) – Analysts at Maxim Group issued their Q2 2026 earnings per share estimates for KindlyMD in a research report issued on Wednesday, May 27th. Maxim Group analyst M. Galinko forecasts that the company will post earnings per share of ($0.41) for the quarter. Maxim Group currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for KindlyMD’s current full-year earnings is ($16.80) per share. Maxim Group also issued estimates for KindlyMD’s Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.60) EPS, Q1 2027 earnings at ($0.87) EPS, Q2 2027 earnings at ($0.88) EPS, Q3 2027 earnings at $0.72 EPS, Q4 2027 earnings at ($0.41) EPS and FY2027 earnings at ($1.44) EPS.

KindlyMD (NASDAQ:NAKA) last posted its earnings results on Wednesday, May 13th. The company reported ($15.20) earnings per share for the quarter. The company had revenue of $2.68 million during the quarter. KindlyMD had a negative net margin of 7,397.12% and a negative return on equity of 81.32%.

A number of other research firms also recently issued reports on NAKA. Weiss Ratings raised KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. B. Riley Financial decreased their target price on KindlyMD from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, February 23rd. TD Cowen began coverage on KindlyMD in a research note on Friday, April 10th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Wall Street Zen raised KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, KindlyMD has an average rating of “Hold” and a consensus price target of $30.00.

KindlyMD Trading Up 3.7%

Shares of NAKA opened at $5.60 on Friday. The stock has a 50 day moving average of $8.21 and a 200 day moving average of $13.07. KindlyMD has a 12 month low of $4.50 and a 12 month high of $995.60. The company has a market capitalization of $97.44 million, a price-to-earnings ratio of -0.13 and a beta of 17.12.

Institutional Investors Weigh In On KindlyMD

Hedge funds have recently added to or reduced their stakes in the company. Osaic Holdings Inc. purchased a new position in shares of KindlyMD in the second quarter worth about $215,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of KindlyMD in the third quarter worth about $369,000. Geode Capital Management LLC increased its holdings in shares of KindlyMD by 76.2% in the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock worth $484,000 after buying an additional 8,386 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of KindlyMD by 1,638.4% in the third quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company’s stock worth $827,000 after buying an additional 31,245 shares during the period. Finally, CI Investments Inc. purchased a new position in shares of KindlyMD in the third quarter worth about $995,000.

Insider Transactions at KindlyMD

In other news, CEO David F. Bailey purchased 55,115 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was purchased at an average price of $5.62 per share, with a total value of $309,746.30. Following the completion of the purchase, the chief executive officer directly owned 3,175,476 shares in the company, valued at approximately $17,846,175.12. This trade represents a 1.77% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders bought a total of 191,448 shares of company stock worth $992,908 over the last three months. Insiders own 24.49% of the company’s stock.

KindlyMD News Summary

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David Bailey bought 104,833 shares at an average price of $4.84, adding to a series of recent open-market purchases and lifting his ownership stake, which may reassure investors about management’s confidence in KindlyMD. Article Title
• Positive Sentiment: Maxim Group reiterated a Buy rating and $30 price target, with forecasted improvement in later-period earnings, which could help support sentiment around NAKA. Article Title
• Neutral Sentiment: Maxim’s earnings estimates still call for losses in the near term, but they model a shift to profitability in some periods of fiscal 2027, suggesting the turnaround story remains speculative. Article Title
• Negative Sentiment: The company’s latest reported quarter showed a large EPS loss and weak profitability metrics, which continue to highlight execution risk for investors. Article Title

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.